Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NTHI

NeOnc Technologies Holdings Inc

May 29 • 04:00PM ET

4.64

-0.15 -3.13 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: AARD AGEN BMEA CNTB GALT GNLX IMUX KZIA SPRO VRCA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.84	Insider Own	82.56%	Shs Outstand	24.13M	Perf Week	-13.43%
Market Cap	120.70M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	0.38%	Shs Float	4.54M	Perf Month	7.91%
Enterprise Value	120.91M	PEG	-	EPS next Q	-0.16	Inst Own	11.25%	Short Float	5.16%	Perf Quarter	-54.60%
Income	-38.64M	P/S	-	EPS this Y	74.17%	Inst Trans	26.47%	Short Ratio	3.49	Perf Half Y	-47.51%
Sales	0.00M	P/B	-	EPS next Y	24.90%	ROA	-656.48%	Short Interest	0.23M	Perf YTD	-43.89%
Book/sh	-0.55	P/C	862.13	EPS next 5Y	40.67%	ROE	-	52W High	12.99 -64.28%	Perf Year	-37.13%
Cash/sh	0.01	P/FCF	-	EPS past 3/5Y	-176.88% -109.20%	ROIC	-	52W Low	3.20 45.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.98% -	Gross Margin	-	Volatility	6.39% 11.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.08	EPS Q/Q	81.93%	SMA20	-10.92%	Beta	0.34	Target Price	16.00
Payout	-	Debt/Eq	-	Sales Q/Q	-100.00%	SMA50	-16.77%	Rel Volume	0.41	Prev Close	4.79
Employees	5	LT Debt/Eq	-	Earnings	May 18 BMO	SMA200	-43.71%	Avg Volume	67.19K	Price	4.64
IPO	Mar 26, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-73.52% -	Trades		Volume	27,847	Change	-3.13%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Initiated	Alliance Global Partners	Buy	$13
May-18-26	Initiated	Maxim Group	Buy	$20
Apr-24-26	Initiated	BTIG Research	Buy	$15

Today 09:05AM	The Next Great AI Revolution May Be Drug Delivery (GlobeNewswire)
May-19-26 10:28AM	NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones (GlobeNewswire)
May-18-26 09:00AM	NeOnc Provides Business Update and Reports Q1 2026 Financial Results (GlobeNewswire)
May-07-26 08:45AM	Biotech's Next Wave May Already be in Motion (GlobeNewswire) +22.22%
May-05-26 09:00AM	NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts (GlobeNewswire) +20.53%
09:00AM	Loading…
Apr-14-26 09:00AM	NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results (GlobeNewswire)
Apr-01-26 09:00AM	NeOnc Provides Business Update and Reports Q4 2025 Financial Results (GlobeNewswire) -13.12%
Mar-13-26 09:00AM	NeOnc Technologies Appoints David Choi as Chief Accounting Officer (GlobeNewswire)
Mar-12-26 08:52AM	Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) (Newsfile)
Mar-04-26 08:00AM	NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET (GlobeNewswire)
Feb-27-26 09:00AM	NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity (GlobeNewswire)
Jan-30-26 09:00AM	NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management (GlobeNewswire) +5.94%
Jan-09-26 07:32PM	Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) (Newsfile)
Dec-15-25 09:00AM	NeOnc Technologies Reports Updated Clinical Results (GlobeNewswire)
Dec-01-25 09:00AM	NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors (GlobeNewswire)
04:01PM	Loading…
Nov-14-25 04:01PM	NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update (GlobeNewswire) -12.33%
Nov-13-25 09:00AM	NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) (GlobeNewswire) -24.09%
Nov-12-25 08:00AM	NeOnc Technologies Reports Updated Clinical Results (GlobeNewswire)
Nov-07-25 09:00AM	NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program (GlobeNewswire)
Nov-04-25 09:00AM	NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth (GlobeNewswire)
Oct-28-25 09:00AM	His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment (GlobeNewswire) +6.92%
Oct-09-25 09:00AM	NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors (GlobeNewswire)
Oct-06-25 09:00AM	NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals (GlobeNewswire)
Oct-02-25 09:00AM	NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board (GlobeNewswire) +15.40%
Oct-01-25 09:00AM	NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board (GlobeNewswire) +8.70%
Sep-29-25 09:00AM	NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board (GlobeNewswire) -11.39%
Sep-22-25 09:00AM	NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on "Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT (GlobeNewswire)
Sep-10-25 09:00AM	NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer (GlobeNewswire) +17.10%
Aug-25-25 09:00AM	NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board (GlobeNewswire)
Aug-19-25 09:00AM	NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update (GlobeNewswire)
09:00AM	Loading…
Aug-11-25 09:00AM	NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation (GlobeNewswire) +6.68%
Aug-07-25 09:00AM	NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia (GlobeNewswire)
Aug-04-25 09:00AM	NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer (GlobeNewswire)
Jul-30-25 09:00AM	NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors (GlobeNewswire)
Jul-29-25 09:00AM	NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment (GlobeNewswire) -7.76%
Jul-28-25 09:00AM	NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference (GlobeNewswire) +6.08%
Jul-23-25 10:53AM	CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc. (GlobeNewswire)
09:00AM	NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks - Today at 11:00 a.m. ET (GlobeNewswire)
Jul-22-25 09:00AM	NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment (GlobeNewswire)
Jul-10-25 09:00AM	NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment (GlobeNewswire) -18.05%
Jul-09-25 09:00AM	NeOnc Technologies Holdings, Inc. Joins Russell Microcap Index (GlobeNewswire)
Jul-08-25 09:00AM	NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform (GlobeNewswire)
Jun-06-25 09:00AM	NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs (GlobeNewswire)
Apr-15-25 08:05AM	NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets (GlobeNewswire)
Apr-14-25 08:05AM	NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September (GlobeNewswire) -12.06%
Apr-10-25 08:05AM	NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President (GlobeNewswire) -10.00%
Apr-08-25 04:05PM	NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy (GlobeNewswire)
Mar-31-25 08:05AM	NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas (GlobeNewswire) -19.27%
Mar-28-25 11:15PM	U.S. IPO Weekly Recap: CoreWeave Fails To Impress In Downsized IPO, As More Names Join The Pipeline (Seeking Alpha) +37.92%
Mar-27-25 08:05AM	NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments (GlobeNewswire)

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

PresidentMr. Amir Farrokh Heshmatpour

Ph.D.Dr. Thomas C. Chen M.D.

Chief Financial OfficerMr. Keithly A. Garnett

Chief Clinical OfficerDr. Josh Neman-Ebrahim Ph.D.

Chief Accounting OfficerMr. David Choi Jr.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heshmatpour Amir F	President	May 01 '26	Buy	4.16	10,000	41,592	3,072,000	May 04 02:08 PM
Heshmatpour Amir F	President	Apr 28 '26	Buy	4.52	10,000	45,180	3,062,000	Apr 28 06:00 PM
Neman-Ebrahim Yousha	Chief Clinical Officer	Apr 23 '26	Buy	4.88	500	2,440	134,760	Apr 24 06:10 PM
Heshmatpour Amir F	President	Apr 23 '26	Buy	4.90	10,000	49,000	3,052,000	Apr 23 09:34 PM
SUH, DAVID JR.	Chief Accounting Officer	Apr 09 '26	Buy	5.00	200	1,000	111,866	Apr 13 06:15 PM
Heshmatpour Amir F	President	Apr 10 '26	Buy	4.89	10,000	48,950	3,042,000	Apr 10 03:29 PM
Heshmatpour Amir F	President	Apr 08 '26	Buy	5.61	10,000	56,050	3,027,000	Apr 09 02:43 PM
Heshmatpour Amir F	President	Apr 09 '26	Buy	5.19	5,000	25,950	3,032,000	Apr 09 02:43 PM
Heshmatpour Amir F	President	Apr 02 '26	Buy	6.09	20,000	121,798	3,012,000	Apr 06 08:55 PM
Heshmatpour Amir F	President	Apr 06 '26	Buy	6.32	5,000	31,600	3,017,000	Apr 06 08:55 PM
Heshmatpour Amir F	President	Nov 21 '25	Buy	6.07	24,000	145,600	2,986,000	Nov 24 09:10 PM
Heshmatpour Amir F	President	Nov 24 '25	Buy	6.51	6,000	39,060	2,992,000	Nov 24 09:10 PM
Neman-Ebrahim Yousha	Chief Clinical Officer	Nov 20 '25	Buy	6.69	1,100	7,359	134,260	Nov 24 05:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTHI

NeOnc Technologies Holdings Inc

Upgrade your Finviz experience